振动治疗对重症成人身体功能影响的随机对照试验
这项单中心随机对照试验纳入180例ICU期间能坐在床沿或轮椅上的患者,随机分为振动治疗联合方案化 mobilize 组(86例)与单独方案化 mobilize 组(90例)。主要终点为ICU出院时FSS-ICU总分,干预组24(18-27) vs 对照组21(17-26),P=0.09,未达统计学显著。次要终点(MRC评分、ICU获得性衰弱、谵妄、IMS、无呼吸机和无ICU天数)均无显著差异。预设亚组分析中,BMI≥23 kg/m²、APACHE II<19、IMS≥6的患者FSS-ICU改善。振动治疗期间生命体征稳定,无不良事件。
要点
- 主要终点:ICU出院时FSS-ICU总分干预组24(18-27) vs 对照组21(17-26),P=0.09,未达统计学显著。
- FSS-ICU中的卧位到坐位能力在干预组显著改善(P<0.01)。
- 次要终点MRC评分、ICU获得性衰弱、谵妄、IMS、无呼吸机和无ICU天数均无显著差异。
- 预设亚组分析:BMI≥23 kg/m²、APACHE II<19、IMS≥6的患者FSS-ICU改善。
- 振动治疗期间生命体征稳定,无不良事件报告。
适用人群与场景
- 纳入ICU期间能坐在床沿或轮椅上的重症成人患者。
- 排除标准基于早期 mobilize 抑制标准。
处置流程与药物剂量
- 干预组:振动治疗联合方案化 mobilize;对照组:单独方案化 mobilize。
- 振动治疗期间监测生命体征以评估安全性。
研究设计与关键结果
- 研究类型:随机对照试验;单中心ICU;样本量180例(振动治疗组86例,对照组90例)。
- 人群:平均年龄振动治疗组69±13岁 vs 对照组67±16岁;APACHE II评分振动治疗组19(14-25) vs 对照组18(13-23)。
- 主要终点:ICU出院时FSS-ICU总分振动治疗组24(18-27) vs 对照组21(17-26),P=0.09。
- 次要终点:MRC评分、ICU获得性衰弱、谵妄、IMS、无呼吸机和无ICU天数均无显著差异。
- 预设亚组分析:BMI≥23 kg/m²、APACHE II<19、IMS≥6的患者FSS-ICU改善。
- 安全性:振动治疗期间生命体征稳定,无不良事件。
证据类型、等级与局限
- 证据类型:随机对照试验(单中心)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 振动治疗未改善ICU出院时FSS-ICU总分,但可改善卧位到坐位能力且无不良事件,作者认为该结果支持振动治疗在此类患者中的安全性。
- 对于BMI≥23 kg/m²、APACHE II<19、IMS≥6的患者,振动治疗可能改善FSS-ICU,但需进一步研究验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Vibration therapy uses vibration to rehabilitate physical functions. Recently, it has been demonstrated to be safe for critically ill patients. However, its effects on physical functions are unclear.
DESIGN: Randomized controlled trial.
SETTING: A single-center, ICU.
PATIENTS: Patients were randomly assigned to either vibration therapy coupled with protocolized mobilization or protocolized mobilization alone. We included patients who could sit at the edge of the bed or in a wheelchair during their ICU stay. The exclusion criteria were based on the early mobilization inhibition criteria.
INTERVENTIONS: The primary outcome was the Functional Status Score for the ICU (FSS-ICU) at ICU discharge. Secondary outcomes were the Medical Research Council score, ICU-acquired weakness, delirium, ICU Mobility Scale (IMS), and ventilator- and ICU-free days. For safety assessment, vital signs were monitored during the intervention.
MEASUREMENTS AND MAIN RESULTS: Among 180 patients, 86 and 90 patients remained in the vibration therapy and control groups, respectively. The mean age was 69 ± 13 vs. 67 ± 16 years in the vibration therapy and control groups, and the Acute Physiology and Chronic Health Evaluation (APACHE) II score was 19 (14-25) vs. 18 (13-23). The total FSS-ICU at ICU discharge was 24 (18-27) and 21 (17-26) in the intervention and control groups, respectively ( p = 0.09), and the supine-to-sit ability significantly improved in the intervention group ( p < 0.01). The secondary outcomes were not significantly different. Vital signs remained stable during vibration therapy. In the predefined subgroup analysis, FSS-ICU improved in the population with a higher body mass index (≥ 23 kg/m 2 ), lower APACHE II scores (< 19), and higher IMS scores (≥ 6).
CONCLUSIONS: Vibration therapy did not improve the total FSS-ICU. However, the supine-to-sit ability in the FSS-ICU improved without any adverse event.
参考来源
- Doi S, Nakanishi N, Kawahara Y, et al. Effects of Vibration Therapy on the Physical Function of Critically Ill Adults Trial: A Randomized Controlled Trial. Crit Care Med. 2024. PMID: 38277179. doi:10.1097/CCM.0000000000006210
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。